Analytical Data
-
Gene name
CCR8
- Application
-
Species
Cynomolgus
-
Source
E. coli
-
Tag
N- His-SUMO
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
G7NYJ2
-
Expression Region
1-355aa
-
Molecular Weight
54.0 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CCR8 (C-C chemokine receptor type 8) is a chemokine receptor that plays a significant role in immune system regulation, particularly in the migration and activation of various immune cell types, including T-cells and regulatory T-cells. Its involvement in immune responses makes it a relevant target for studying diseases such as asthma, autoimmune disorders, and cancer. CCR8 is known to bind specific chemokines, thereby influencing the recruitment of immune cells to sites of inflammation. Understanding the structure and function of CCR8 is critical for developing therapeutic strategies aimed at modulating immune responses. Recent advances in recombinant protein technology have enabled researchers to produce and study CCR8 as a recombinant protein, allowing for detailed investigations of its binding properties, signaling pathways, and potential as a drug target. The recombinant CCR8 protein can be utilized in various assays to explore its interactions with ligands and inhibitors, which is instrumental in drug discovery processes. Additionally, as CCR8 is expressed on certain tumor-infiltrating lymphocytes, studying its role may provide insights into the tumor microenvironment and aid in the development of immunotherapies. Overall, research on CCR8 and its recombinant variants holds promise for advancing our understanding of immune regulation and developing novel treatments for immune-related diseases.
